Sexual function and chemotherapy in postmenopausal women with breast cancer

Autor: Rodrigo Cericatto, Carlos Henrique Menke, Fernando Schuh, José Antônio Crespo Cavalheiro, Caroline Vieira Pinheiro, Jorge Villanova Biazús, Nilton Leite Xavier, Ana Cristina da Costa Bittelbrunn, Eduardo Pandolfi Passos
Jazyk: angličtina
Předmět:
Oncology
Cross-sectional study
Comportamento sexual
Cohort Studies
Breast cancer
Surveys and Questionnaires
Antineoplastic Combined Chemotherapy Protocols
Obstetrics and Gynaecology
Sexual Dysfunctions
Psychological
Medicine(all)
Antibiotics
Antineoplastic
lcsh:Public aspects of medicine
Obstetrics and Gynecology
FSFI
General Medicine
Middle Aged
Postmenopause
Female
medicine.symptom
Sexuality
Research Article
Cohort study
medicine.drug
medicine.medical_specialty
Cyclophosphamide
Sexual Behavior
Sexual function
Reproductive medicine
Breast Neoplasms
lcsh:Gynecology and obstetrics
Drug Administration Schedule
Internal medicine
medicine
Humans
Chemotherapy
Antineoplastic Agents
Alkylating
lcsh:RG1-991
Aged
Gynecology
business.industry
Case-control study
lcsh:RA1-1270
Neoplasias da mama
medicine.disease
Sexual Dysfunction
Physiological
Cross-Sectional Studies
Sexual dysfunction
Reproductive Medicine
Doxorubicin
Case-Control Studies
Sexualidade
Quimioterapia
business
Zdroj: Repositório Institucional da UFRGS
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
BMC Women's Health, Vol 12, Iss 1, p 28 (2012)
BMC Women's Health
ISSN: 1472-6874
DOI: 10.1186/1472-6874-12-28
Popis: Background This cross-sectional, nested cohort study assessed Female Sexual Function Index (FSFI) scores in postmenopausal women with breast cancer receiving primary chemotherapy. Methods The FSFI questionnaire was administered to 24 postmenopausal women one month after diagnosis of breast cancer (post-diagnosis group) and one month after completion of the first cycle of primary anthracyclin-based chemotherapy (post-chemotherapy group). Scores were compared to those of 24 healthy postmenopausal women seeking routine gynecological care (control group). All patients were sexually active at the time of enrollment. Mean age was 57.29 ± 11.82 years in the breast cancer group and 52.58 ± 7.19 years in the control group. Results Scores in all domains of the FSFI instrument were significantly lower in the post-diagnosis group than in controls (−41.3%, p Conclusion The present study shows that female sexual function as assessed by the FSFI declines significantly at two distinct points in time: upon diagnosis of breast cancer and after administration of systemic chemotherapy.
Databáze: OpenAIRE
Externí odkaz: